Artificial intelligence (AI) and machine learning (ML) hold immense promise for shaping the future of cell and gene therapy (CGT), offering unprecedented opportunities to streamline manufacturing processes, enhance cost efficiency, and expedite market access. As these technologies are relatively novel, a crucial question emerges: What are the potentials and limitations of these innovations and how can we effectively integrate them into our daily manufacturing and clinical practices?
The 2024 Commercialization Signature Series will unite influential leaders from global cell and gene therapy organizations to unravel the complexities surrounding these groundbreaking technologies and explore optimal ways to harness their power for advancing the sector. Interactive tabletop discussions with key industry players, academia experts and regulatory representatives will center on developing strategies and identifying challenges, with a specific focus on seamlessly integrating AI and ML into intricate CGT processes.
Join us in this interactive forum where industry pioneers collaborate to pave the way for a future where cutting-edge technologies revolutionize the landscape of cell and gene therapy commercialization.
This exclusive event is reserved for ISCT Patron Industry members. Become an ISCT Patron today to gain access to this global forum of industry leaders. Contact Simone@ISCTglobal.org
Exclusive to ISCT Patron Industry Members